IGROV-1

The IGROV-1 cell line is a well-characterized human ovarian adenocarcinoma line, originally established in 1985 from a stage III solid primary tumor of a 47-year-old female patient with no prior chemotherapy treatment. It exhibits an epithelial morphology, adheres as a monolayer in culture, and possesses a doubling time of approximately 20 hours.

A key advantage of the IGROV-1 cell line lies in its distinctive genetic and mutational profile, which uniquely spans both Type I and Type II ovarian cancer signatures. It harbors heterozygous mutations in TP53, BRCA1, PTEN, PIK3CA and ARID1A, and is considered a likely representative of the Type II high-grade serous carcinoma (HGSC) with SET-like morphology. The line is also identified by specific cytogenetic markers, including a paracentric inversion of chromosome 3 and a translocation between chromosomes 2 and 5. Furthermore, it exhibits a hypermutation phenotype, making it an excellent model for genomic instability and DNA damage response research.

From a research application perspective, the IGROV-1 cell line is widely recognized as an established model for drug-resistant ovarian carcinoma. While it retains sensitivity to cisplatin, it demonstrates low to moderate resistance to various other chemotherapeutics, making it an ideal platform for investigating drug resistance mechanisms. Moreover, beyond oncology, it has emerged as a robust in vitro system for virology, with notable susceptibility to SARS-CoV-2 and the ability to mount innate immune responses.